EMBO Molecular Medicine (Sep 2021)

Dependence receptors: new targets for cancer therapy

  • Morgan Brisset,
  • Mélodie Grandin,
  • Agnès Bernet,
  • Patrick Mehlen,
  • Frédéric Hollande

DOI
https://doi.org/10.15252/emmm.202114495
Journal volume & issue
Vol. 13, no. 11
pp. 1 – 14

Abstract

Read online

Abstract Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, allowing cancer cells to escape apoptosis triggered by these receptors while promoting in parallel major aspects of tumorigenesis such as proliferation, angiogenesis, invasiveness, and chemoresistance. This involvement in multiple cancer hallmarks has raised interest in dependence receptors as targets for cancer therapy. Although additional studies remain necessary to fully understand the complexity of signaling pathways activated by these receptors and to target them efficiently, it is now clear that dependence receptors represent very exciting targets for future cancer treatment. This manuscript reviews current knowledge on the contribution of dependence receptors to cancer and highlights the potential for therapies that activate pro‐apoptotic functions of these proteins.

Keywords